

Brivaracetam information sheet

Document history:

Version	Date	Main Changes/Comments
1	July 2021	Adapted from the 2018 East Kent prescribing group Brivaracetam information sheet . Contact details removed and information that is duplicated in summary of product characteristics removed. Age range amended as per SPC. Document sent to EKUFT, no comments received.

Specialist Initiated Drugs

Brivaracetam

July 2021

Brivaracetam (Briviact®) - Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Formulations available on Formulary

Film coated tablets available in 10mg, 25mg, 50mg, 75mg and 100mg , Oral solution: 10 mg/ml

Solution for injection/infusion: 10 mg/ml – **Hospital Only**

Prescribing

Initiation:

The specialist will prescribe the most appropriate formulation and strength according to weight, dose and age and adjust the dose until the patient is stable.

The responsibility for increasing/decreasing the dose or stopping treatment due to lack of effect or side effects remains with the specialist. They should be consulted if a change in treatment is required.

Specialist services should respond to any queries from primary care prescribers within 48 hours

Continuation:

On-going prescribing can be continued by a GP.

For additional information please see the Summary of Product Characteristics
<http://www.medicines.org.uk/emc/medicine/31452>

References

Summary of Product Characteristics Briviact®, UCB Pharma Limited updated 08-Jun-2021
<http://www.medicines.org.uk/emc/medicine/31452>

Approved by: JPC, KMMOC and Clinical Cabinet
Approval Date: Ratified by Clinical Cabinet December 2021
Review Date: December 2023